// App-Quantinova.ai

5013 : AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy.

Researchers

Presenter

  • Howard I. Scher

Principal Investigators

  • Ryon Graf

  • Nicole A. Schreiber

  • Brigit McLaughlin

  • David Lu

  • Jessica Louw

  • Adam Jendrisak

  • Stephanie Greene

  • Angel Rodriguez

  • Lyndsey Dugan

  • Martin Fleisher

  • Jerry Lee

  • Yipeng Wang

  • Mark Andrew Landers

  • Ryan Vance Dittamore

Medical Centers

  • Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Epic Sciences, Inc., San Diego, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Epic Sciences, Inc., San Diego, CA

Locations

  • United States

Companies

  • EPIC SCIENCES, INC.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Androgen receptor variant 7

  • Circulating tumor cells

Drug/Treatment

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved